China’s state-owned pharma company Sinopharm’s Covid-19 vaccine has received emergency use authorisation (EUA) from the World Health Organization (WHO). Sinopharm’s vaccine is the first Covid-19 vaccine developed by a non-western country to get approval from the WHO. The approval was based on a review of latest clinical data and manufacturing practices of the vaccine.
The European Medicines Agency (EMA) has initiated a rolling review of data on GlaxoSmithKline and Vir Biotechnology’s investigational dual-action SARS-CoV-2 monoclonal antibody, sotrovimab, for treatment of Covid-19 patients aged 12 and older. EMA will assess data on sotrovimab, which includes evidence gathered from clinical trials, as they become available.
Shanghai-based pharma group Fosun Pharma has signed a $200m joint venture agreement with Germany’s BioNTech for domestic production and commercialisation of the latter’s messenger ribonucleic acid (mRNA) Covid-19 vaccine. Fosun Pharma will invest $100m to produce one billion vaccine doses a year, while BioNTech will invest a maximum of $100m in production technology and patents.